FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

Abstract 

Forty-five patients with high-risk myeloid malignancies (32 acute myeloid leukemia and 13 high-risk myelodysplastic syndromes) were treated with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA). Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission. Infection predominantly with pulmonary involvement was the most common regimen-related toxicity. Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects. There were four early deaths and 12 patients presented with resistant disease. Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity.

FLAG-IDA, fludarabine, cytarabine, idarubicin and G-CSF, G-CSF, granulocyte colony-stimulating factor, AML, acute myeloid leukaemia, MDS, myelodysplastic syndromes, CR, complete remission, PR, partial remission, HSCT, hematopoietic stem cell transplantation, OS, overall survival

Myeloid malignancies, High-risk, Fludarabine, Toxicity